期刊文献+

咪喹莫特对人皮肤成纤维细胞活性和凋亡的影响 被引量:8

Imiquimod effects on the apoptosis and activity of fibroblasts in vitro
下载PDF
导出
摘要 目的:观察咪喹莫特(imiquimod)溶液对人真皮成纤维细胞(FB)细胞毒性、细胞增殖及细胞凋亡率的影响,探讨其治疗瘢痕疙瘩的可能机制。方法:分离培养人真皮成纤维细胞,用四甲基偶氮唑蓝(MTT)法检测不同浓度咪喹莫特溶液对成纤维细胞毒性及细胞增殖的影响;用流式细胞技术检测咪喹莫特对成纤维细胞凋亡率的影响。结果:不同浓度咪喹莫特加入成纤维细胞培养体系孵育24h后,成纤维细胞形态均有不同程度受损,且细胞增殖活性下降,尤以20mg/L浓度时细胞活性下降明显;各浓度咪喹莫特处理组细胞凋亡率均高于对照组(P<0.05),但在不同时间点检测的细胞凋亡率差异无统计学意义(P>0.05)。结论:咪喹莫特可以降低成纤维细胞增殖活性并增加细胞凋亡率,这些可能是其促进皮肤瘢痕组织消退的相关机制。 Objective: To observe the effect of imiquimod on the cytotoxicity, the cell proliferation and the apoptosis rate in human skin fibroblasts. Methods: The cytotoxicity and proliferation were detected by MTr. The apoptosis rate was detected by flow cytometry (FCM). Results: In the imiquimod (20 μg/mL) treated groups the fibroblasts were significantly damaged and the proliferation activity was decreased. The cellular apoptosis rates in different concentration of imiquimod-treated groups were statistically higher than those in control group (P 〈 0.05). There was no statistical difference in the rates of apoptosis at the time point experiment (P 〉 0.05). Conclusion: The results indicate that imiquimod could decrease the cellular proliferation activity and increase the apoptosis rate of human skin fibroblasts, which might become one of the possible mechanisms for effectively treating cicatricial tissue.
出处 《临床皮肤科杂志》 CAS CSCD 北大核心 2007年第3期148-150,共3页 Journal of Clinical Dermatology
关键词 咪喹莫特 成纤维细胞 凋亡 细胞 imiquimod fibroblasts apoptosis
  • 相关文献

参考文献9

  • 1骆丹,缪旭,吉玺,吴迪,朱洁,林向飞,徐丽贤.咪喹莫特对朗格汉斯细胞及角质形成细胞细胞因子mRNA表达及分泌水平的影响[J].中华微生物学和免疫学杂志,2006,26(3):274-278. 被引量:3
  • 2Al-Attar A,Mess S,Thomassen JM,et al.Keloid pathogenesis and treatment[J].Plast Reconstr Surg,2006,117(1):286-300.
  • 3Coors EA,Schuler G,Von Den Driesch P.Topical imiquimod as treatment for different kinds of cutaneous lymphoma[J].Eur J Dermatol,2006,16(4):391-393.
  • 4Imbertson LM,Beaurline JM,Couture AM,et al.Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers imiquimod and S-28463[J].J Invest Dermatol,1998,110(5):734-739.
  • 5Meier K,Nanney LB.Emerging new drugs for scar reduction[J].Expert Opin Emerg Drugs,2006,11(1):39-47.
  • 6Patel PJ,Skinner RB Jr.Experience with keloids after excision and application of 5% imiquimod cream[J].Dermatol Surg.2006.32(3):462.
  • 7Martin-Garcia RF,Busquets AC.Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences:resuits of an open-label,pilot study[J].Dermatol Surg,2005,31(11 Pt 1):1394-1398.
  • 8Jacob SE,Berman B,Nassiri M,et al.Topical application of imiquimod 5%cream to keloids alters expression genes associatedwith apoptosis[J].Br J Dermatol,2003,149 Suppl 66:62-65.
  • 9Vidal D,Matias-Guiu X,Alomar A.Efficacy of imiquimod for the expression of Bcl-2,Ki67,p53 and basal cell carcinoma apoptosis[J].Br J Dermatol,2004,151(3):656-662.

二级参考文献11

  • 1缪旭,骆丹,吉玺,林向飞.联用密度梯度离心与免疫磁珠法分离纯化人表皮朗格汉斯细胞[J].临床皮肤科杂志,2005,34(5):276-278. 被引量:8
  • 2Vilata JJ, Badia X. Effectiveness, satisfaction and compliance with Imiquimod in the treatment of external anogenital warts. International Journal of STD & AIDS, 2003, 14(1): 11-17.
  • 3Eklind J, Tartler U, MaschkeJ, et al. Imiquimod to treat different cancers of the epidermis.Dermatologic Surgery, 2003, 29(8): 890-896.
  • 4Stockfleth E, Meyer T, Benninghoff B, et al. Successful treatment of actinic keratosis with Imiqiumod cream 5% : a report of six cases, Br J Dermatol, 2001, 144(5): 1051-1053.
  • 5Wager TL, Horton VL, Carlson GL, et al. Induction of cytokines in cynomolgus monkeys by the immune response modifiers, Imiquimod, S-16598 and S-17352. Cytokine, 1997, 9(11): 837-845.
  • 6Burns RP Jr, Ferbel B, Tomai M, et al. The Imidazoquinolines, Imiquimod and R-848, induce functional, but not phenotypic, maturation of human epidermal Langerhans' cells. Clinical Immunol, 2000, 1(94):13-23.
  • 7Kono T, Kondo S, Pastore S, et al. Effects of a novel topical immunodulator, Imiquimod, on keratinocyte cytokine gene expression. Lymphokine Cytokine Res, 1994, 13: 71-76.
  • 8Suzaki H, Wang B, Shivji GM, et al. Imiquimod, a topical immune response modifier, induces migration of Langerhans cells. J Invest Dermatol, 2000, 114 (1): 135-141.
  • 9Mempel M, Voelcke V, Kollisch G, et al. Toll-like receptor expression human keratinocytes: nuclear factor kB controlled gene activation by Staphylococcus aureus is Toll-like receptor 2 but not Toll-like receptor 4 or playlet activating factor receptor dependent. J Invest Dermatol, 2003,121(6) : 1389-1396.
  • 10Imbertson LM, Beaurline JM, Couture AM, et al. Cytokine induction in hairless mouse and rat skin after topical application of the immune response modifiers Imiquimod and S28463. J Invest Dermatol, 1998, 110(5) : 734-739.

共引文献2

同被引文献101

引证文献8

二级引证文献42

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部